Aberrant insulin signaling in Alzheimer's disease: Current knowledge

Frontiers in Neuroscience

Volumn 9, Issue MAY, 2015, Pages

  Bedse, Gaurav ^a   Di Domenico, Fabio ^a   Serviddio, Gaetano ^b   Cassano, Tommaso ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Alzheimer's disease; Beta amyloid; Insulin signaling; Insulin like growth factor; Phosphorylated tau

Indexed keywords

AMYLOID BETA PROTEIN; INSULIN; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; BRAIN LEVEL; COGNITION; HUMAN; INSULIN BRAIN LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SIGNALING; MEMORY; NEUROFIBRILLARY TANGLE; SENILE PLAQUE; SIGNAL TRANSDUCTION;

EID: 84931271345     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2015.00204     Document Type: Article

References (141)

1. Ashpole, N.M., Sanders, J.E., Hodges, E.L., Yan, H., and Sonntag, W.E. (2014). Growth hormone, insulin-like growth factor-1 and the aging brain. Exp Gerontol. doi: 10.1016/j.exger.2014.10.002.
2. Aulston, B.D., Odero, G.L., Aboud, Z., and Glazner, G.W. (2013). Alzheimer's Disease and Diabetes, Understanding Alzheimer's Disease. doi: 10.5772/54913, Prof. Inga Zerr (Ed.), ISBN: 978-953-51-1009-5, InTech. Available from: http://www.intechopen.com/books/understanding-alzheimer477
3. Authier, F., Posner, B.I., and Bergeron, J.J. (1996). Insulin-degrading enzyme. Clin Invest Med 19, 149-160.
4. Baker, L.D., Cross, D.J., Minoshima, S., Belongia, D., Watson, G.S., and Craft, S. (2011). Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 68, 51-57. doi: 10.1001/archneurol.2010.225.
5. Banks, W.A., Owen, J.B., and Erickson, M.A. (2012). Insulin in the brain: there and back again. Pharmacol Ther 136, 82-93. doi: 10.1016/j.pharmthera.2012.07.006.
6. Bedse, G., Romano, A., Lavecchia, A.M., Cassano, T., and Gaetani, S. (2014). The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer's Disease. J Alzheimers Dis. doi: 10.3233/jad-141635.
7. Benedict, C., Frey, W.H., 2nd, Schioth, H.B., Schultes, B., Born, J., and Hallschmid, M. (2011). Intranasal insulin as a therapeutic option in the treatment of cognitive impairments. Exp Gerontol 46, 112-115. doi: 10.1016/j.exger.2010.08.026.
8. Benedict, C., Hallschmid, M., Hatke, A., Schultes, B., Fehm, H.L., Born, J., and Kern, W. (2004). Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29, 1326-1334. doi: 10.1016/j.psyneuen.2004.04.003.
9. Benedict, C., Hallschmid, M., Schmitz, K., Schultes, B., Ratter, F., Fehm, H.L., Born, J., and Kern, W. (2007). Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 32, 239-243. doi: 10.1038/sj.npp.1301193.
10. Benedict, C., Kern, W., Schultes, B., Born, J., and Hallschmid, M. (2008). Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab 93, 1339-1344. doi: 10.1210/jc.2007-2606.
11. Bolotina, V.M., Najibi, S., Palacino, J.J., Pagano, P.J., and Cohen, R.A. (1994). Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 368, 850-853. doi: 10.1038/368850a0.
12. Bomfim, T.R., Forny-Germano, L., Sathler, L.B., Brito-Moreira, J., Houzel, J.C., Decker, H., Silverman, M.A., Kazi, H., Melo, H.M., Mcclean, P.L., Holscher, C., Arnold, S.E., Talbot, K., Klein, W.L., Munoz, D.P., Ferreira, S.T., and De Felice, F.G. (2012). An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers. J Clin Invest 122, 1339-1353. doi: 10.1172/jci57256.
13. Born, J., Lange, T., K ern, W., Mcgregor, G.P., Bickel, U., and Fehm, H.L. (2002). Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5, 514-516. doi: 10.1038/nn849.
14. Brodbeck J., Balestra M.E., Saunders A.M., Roses A.D., Mahley R.W., and Huang Y. (2008) Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons. PNAS 105, 1343-1346. doi: 10.1073/pnas.0709906104.
15. Bucht, G., Adolfsson, R., Lithner, F., and Winblad, B. (1983). Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. Acta Med Scand 213, 387-392.
16. Butterfield, D.A., Di Domenico, F., and Barone, E. (2014a). Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim Biophys Acta 1842, 1693-1706. doi: 10.1016/j.bbadis.2014.06.010.
17. Butterfield, D.A., Gu, L., Di Domenico, F., and Robinson, R.A. (2014b). Mass spectrometry and redox proteomics: applications in disease. Mass Spectrom Rev 33, 277-301. doi: 10.1002/mas.21374.
18. Carro, E., Trejo, J.L., Gomez-Isla, T., Leroith, D., and Torres-Aleman, I. (2002). Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8, 1390-1397. doi: 10.1038/nm793.
19. Chen, Y., Deng, Y., Zhang, B., and Gong, C.X. (2014a). Deregulation of brain insulin signaling in Alzheimer's disease. Neurosci Bull 30, 282-294. doi: 10.1007/s12264-013-1408-x.
20. Chen, Y., Liang, Z., Blanchard, J., Dai, C.L., Sun, S., Lee, M.H., Grundke-Iqbal, I., Iqbal, K., Liu, F., and Gong, C.X. (2013). A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol 47, 711-725. doi: 10.1007/s12035-012-8375-5.
21. Chen, Y., Run, X., Liang, Z., Zhao, Y., Dai, C.L., Iqbal, K., Liu, F., and Gong, C.X. (2014b). Intranasal insulin prevents anesthesia-induced hyperphosphorylation of tau in 3xTg-AD mice. Front Aging Neurosci 6, 100. doi: 10.3389/fnagi.2014.00100.
22. Chen, Y., Zhao, Y., Dai, C.L., Liang, Z., Run, X., Iqbal, K., Liu, F., and Gong, C.X. (2014c). Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Abeta level and microglia activation in the brains of 3xTg-AD mice. Exp Neurol 261, 610-619. doi: 10.1016/j.expneurol.2014.06.004.
23. Cheng, C.M., Tseng, V., Wang, J., Wang, D., Matyakhina, L., and Bondy, C.A. (2005). Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology 146, 5086-5091. doi: 10.1210/en.2005-0063.
24. Chung HJ, Huang YH, Lau LF, Huganir RL (2004) Regulation of the NMDA receptor complex and trafficking by activity-dependent phosphorylation of the NR2B subunit PDZ ligand. J Neurosci 24, 10248-10259. doi: 10.1523/JNEUROSCI.0546-04.2004
25. Churcher, I. (2006). Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr Top Med Chem 6, 579-595. doi: 10.2174/156802606776743057
26. Claxton, A., Baker, L.D., Hanson, A., Trittschuh, E.H., Cholerton, B., Morgan, A., Callaghan, M., Arbuckle, M., Behl, C., and Craft, S. (2014). Long-Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer's Disease Dementia. J Alzheimers Dis. doi: 10.3233/jad-141791.
27. Conejo, R., and Lorenzo, M. (2001). Insulin signaling leading to proliferation, survival, and membrane ruffling in C2C12 myoblasts. J Cell Physiol 187, 96-108. doi: 10.1002/1097-4652(2001)9999:9999<::aid-jcp1058>3.0.co;2-v.
28. Craft, S. (2007). Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4, 147-152. doi: 10.2174/156720507780362137
29. Craft, S., Baker, L.D., Montine, T.J., Minoshima, S., Watson, G.S., Claxton, A., Arbuckle, M., Callaghan, M., Tsai, E., Plymate, S.R., Green, P.S., Leverenz, J., Cross, D., and Gerton, B. (2012). Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69, 29-38. doi: 10.1001/archneurol.2011.233.
30. Craft, S., Dagogo-Jack, S.E., Wiethop, B.V., Murphy, C., Nevins, R.T., Fleischman, S., Rice, V., Newcomer, J.W., and Cryer, P.E. (1993). Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci 107, 926-940.
31. Craft, S., Newcomer, J., Kanne, S., Dagogo-Jack, S., Cryer, P., Sheline, Y., Luby, J., Dagogo-Jack, A., and Alderson, A. (1996). Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 17, 123-130. doi:10.1016/0197-4580(95)02002-0
32. Craft, S., Peskind, E., Schwartz, M.W., Schellenberg, G.D., Raskind, M., and Porte, D., Jr. (1998). Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164-168.
33. Craft, S., and Watson, G.S. (2004). Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3, 169-178. doi: 10.1016/s1474-4422(04)00681-7.
34. Cruts, M., and Van Broeckhoven, C. (1998). Molecular genetics of Alzheimer's disease. Ann Med 30, 560-565.
35. Cusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M.E., Pratipanawatr, T., Defronzo, R.A., Kahn, C.R., and Mandarino, L.J. (2000). Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 105, 311-320. doi: 10.1172/jci7535.
36. De Felice, F.G. (2013). Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J Clin Invest 123, 531-539. doi: 10.1172/jci64595.
37. De Felice, F.G., Vieira, M.N., Bomfim, T.R., Decker, H., Velasco, P.T., Lambert, M.P., Viola, K.L., Zhao, W.Q., Ferreira, S.T., and Klein, W.L. (2009). Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A 106, 1971-1976. doi: 10.1073/pnas.0809158106.
38. de la Monte SM. (2012) Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res. 9, 35-66. doi: 10.2174/156720512799015037
39. De La Monte, S.M. (2012a). Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 72, 49-66. doi: 10.2165/11597760-000000000-00000.
40. De La Monte, S.M. (2012b). Triangulated mal-signaling in A lzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J Alzheimers Dis 30 Suppl 2, S231-249. doi: 10.3233/jad-2012-111727.
41. De La Monte, S.M. (2014). Type 3 diabetes is sporadic Alzheimers disease: mini review. Eur Neuropsychopharmacol 24, 1954-1960. doi: 10.1016/j.euroneuro.2014.06.008.
42. De La Monte, S.M., Longato, L., Tong, M., and Wands, J.R. (2009). Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non alcoholic steatohepatitis. Curr Opin Investig Drugs 10, 1049-1060.
43. Dekosky, S.T., and Scheff, S.W. (1990). Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 27, 457-464. doi: 10.1002/ana.410270502.
44. Deng, Y., Li, B., Liu, Y., Iqbal, K., Grundke-Iqbal, I., and Gong, C.X. (2009). Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol 175, 2089-2098. doi: 10.2353/ajpath.2009.090157.
45. Dore, S., Kar, S., Rowe, W., and Quirion, R. (1997). Distribution and levels of [125I]IGF-I, [125I]IGF-II and [125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats. Neuroscience 80, 1033-1040.
46. Duarte, A.I., Moreira, P.I., and Oliveira, C.R. (2012). Insulin in central nervous system: more than just a peripheral hormone. J Aging Res 2012, 384017. doi: 10.1155/2012/384017.
47. Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E.A., Frosch, M.P., Eckman, C.B., Tanzi, R.E., Selkoe, D.J., and Guenette, S. (2003). Insulin degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100, 4162-4167. doi: 10.1073/pnas.0230450100.
48. Fernandez, A.M., and Torres-Aleman, I. (2012). The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci 13, 225-239. doi: 10.1038/nrn3209.
49. Formoso, G., Chen, H., Kim, J.A., Montagnani, M., Consoli, A., and Quon, M.J. (2006). Dehydroepiandrosterone mimics acute actions of insulin to stimulate production of both nitric oxide and endothelin 1 via distinct phosphatidylinositol 3-kinase- and mitogen-activated protein kinase-dependent pathways in vascular endothelium. Mol Endocrinol 20, 1153-1163. doi: 10.1210/me.2005-0266.
50. Freude, S., Plum, L., Schnitker, J., Leeser, U., Udelhoven, M., Krone, W., Bruning, J.C., and Schubert, M. (2005). Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 54, 3343-3348.
51. Freiherr J, Hallschmid M, Frey WH, Brünner YF, Chapman CD, Hölscher C, Craft S, De Felice FG, Benedict C., (2013) Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs, 27, 505-514. doi: 10.1007/s40263-013-0076-8.
52. Frolich, L., Blum-Degen, D., Bernstein, H.G., Engelsberger, S., Humrich, J., Laufer, S., Muschner, D., Thalheimer, A., Turk, A., Hoyer, S., Zochling, R., Boissl, K.W., Jellinger, K., and Riederer, P. (1998). Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 105, 423-438.
53. Fuenzalida, K.; Quintanilla, R.; Ramos, P.; Piderit, D., Fuentealba, R.A.; Martinez, G.; Inestrosa, N.C.; Bronfman, M. (2007) Peroxisome Proliferator-activated Receptor γ Up-regulates the Bcl-2 Anti- apoptotic Protein in Neurons and Induces Mitochondrial Stabilization and Protection against Oxidative Stress and Apoptosis. J. Biol.Chem., 282, 37006-37015. doi: 10.1074/jbc.M700447200
54. Fujisawa, Y., Sasaki, K., and Akiyama, K. (1991). Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol Psychiatry 30, 1219-1228.
55. Gabuzda, D., Busciglio, J., Chen, L.B., Matsudaira, P., and Yankner, B.A. (1994). Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269, 13623-13628.
56. Gasparini, L., Gouras, G.K., Wang, R., Gross, R.S., Beal, M.F., Greengard, P., and Xu, H. (2001). Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 21, 2561-2570.
57. Gasparini, L., Netzer, W.J., Greengard, P., and Xu, H. (2002). Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci 23, 288-293.
58. Gil-Bea, F.J., Solas, M., Solomon, A., Mugueta, C., Winblad, B., Kivipelto, M., Ramirez, M.J., and Cedazo-Minguez, A. (2010). Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease. J Alzheimers Dis 22, 405-413. doi: 10.3233/jad-2010-100795.
59. Hallschmid, M., Schultes, B., Marshall, L., Molle, M., Kern, W., Bredthauer, J., Fehm, H.L., and Born, J. (2004). Transcortical direct current potential shift reflects immediate signaling of systemic insulin to the human brain. Diabetes 53, 2202-2208.
60. Holscher C, Li L. (2010) New roles for insulin-like hormones in neu- ronal signalling and protection: new hopes for novel treatments of Alzheimer's disease? Neurobiol Aging, 31,1495-1502. doi:10.1016/j.neurobiolaging.2008.08.023.
61. Hong, M., and Lee, V.M. (1997). Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272, 19547-19553.
62. Hoyer, S. (2002). The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm 109, 341-360. doi: 10.1007/s007020200028.
63. Hoyer, S. (2004). Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490, 115-125. doi: 10.1016/j.ejphar.2004.02.049.
64. Jiang, Z.Y., Lin, Y.W., Clemont, A., Feener, E.P., Hein, K.D., Igarashi, M., Yamauchi, T., White, M.F., and King, G.L. (1999). Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 104, 447-457. doi: 10.1172/jci5971.
65. Kahn, A.M., Husid, A., Allen, J.C., Seidel, C.L., and Song, T. (1997). Insulin acutely inhibits cultured vascular smooth muscle cell contraction by a nitric oxide synthase-dependent pathway. Hypertension 30, 928-933.
66. Kar, S., Poirier, J., Guevara, J., Dea, D., Hawkes, C., Robitaille, Y., and Quirion, R. (2006). Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology. Neurobiol Aging 27, 199-210. doi: 10.1016/j.neurobiolaging.2005.03.005.
67. Kleinridders, A., Ferris, H.A., Cai, W., and Kahn, C.R. (2014). Insulin action in brain regulates systemic metabolism and brain function. Diabetes 63, 2232-2243. doi: 10.2337/db14-0568.
68. Krikorian, R., Eliassen, J.C., Boespflug, E.L., Nash, T.A., and Shidler, M.D. (2010). Improved cognitive-cerebral function in older adults with chromium supplementation. Nutr Neurosci 13, 116-122. doi: 10.1179/147683010x12611460764084.
69. Krug, R., Benedict, C., Born, J., and Hallschmid, M. (2010). Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory. J Clin Endocrinol Metab 95, E468-472. doi: 10.1210/jc.2010-0744.
70. Kubes, P., Suzuki, M., and Granger, D.N. (1991). Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 88, 4651-4655.
71. Kurochkin, I.V., and Goto, S. (1994). Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 345, 33-37.
72. Lacor, P.N., Buniel, M.C., Furlow, P.W., Clemente, A.S., Velasco, P.T., Wood, M., Viola, K.L., and Klein, W.L. (2007). Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27, 796-807. doi: 10.1523/jneurosci.3501-06.2007.
73. Leissring, M.A., Farris, W., Chang, A.Y., Walsh, D.M., Wu, X., Sun, X., Frosch, M.P., and Selkoe, D.J. (2003). Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093.
74. Lesort, M., and Johnson, G.V. (2000). Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience 99, 305-316.
75. Lester-Coll, N., Rivera, E.J., Soscia, S.J., Doiron, K., Wands, J.R., and De La Monte, S.M. (2006). Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 9, 13-33.
76. Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., and Gong, C.X. (2011). Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 225, 54-62. doi: 10.1002/path.2912.
77. Luchsinger, J.A. (2010). Type 2 diabetes, related conditions, in relation and dementia: an opportunity for prevention? J Alzheimers Dis 20, 723-736. doi: 10.3233/jad-2010-091687.
78. Ma, Q.L., Yang, F., Rosario, E.R., Ubeda, O.J., Beech, W., Gant, D.J., Chen, P.P., Hudspeth, B., Chen, C., Zhao, Y., Vinters, H.V., Frautschy, S.A., and Cole, G.M. (2009). Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 29, 9078-9089. doi: 10.1523/jneurosci.1071-09.2009.
79. Mattson, M.P. (1997). Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 77, 1081-1132.
80. Moloney, A.M., Griffin, R.J., Timmons, S., O'connor, R., Ravid, R., and O'neill, C. (2010). Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IG F-1 and insulin signalling. Neurobiol Aging 31, 224-243. doi: 10.1016/j.neurobiolaging.2008.04.002.
81. Moreira, P.I., Duarte, A.I., Santos, M.S., Rego, A.C., and Oliveira, C.R. (2009). An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimers Dis 16, 741-761. doi: 10.3233/jad-2009-0972.
82. Muller, A.P., Fernandez, A.M., Haas, C., Zimmer, E., Portela, L.V., and Torres-Aleman, I. (2012). Reduced brain insulin-like growth factor I function during aging. Mol Cell Neurosci 49, 9-12. doi: 10.1016/j.mcn.2011.07.008.
83. Mustafa, A., Lannfelt, L., Lilius, L., Islam, A., Winblad, B., and Adem, A. (1999). Decreased plasma insulin-like growth factor-I level in familial Alzheimer's disease patients carrying the Swedish APP 670/671 mutation. Dement Geriatr Cogn Disord 10, 446-451. doi: 17188.
84. Neumann, K.F., Rojo, L., Navarrete, L.P., Farias, G., Reyes, P., and Maccioni, R.B. (2008). Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr Alzheimer Res 5, 438-447.
85. Perez, A., Morelli, L., Cresto, J.C., and Castano, E.M. (2000). Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. Neurochem Res 25, 247-255.
86. Perluigi, M., Pupo, G., Tramutola, A., Cini, C., Coccia, R., Barone, E., Head, E., Butterfield, D.A., and Di Domenico, F. (2014). Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim Biophys Acta 1842, 1144-1153. doi: 10.1016/j.bbadis.2014.04.007.
87. Phiel, C.J., Wilson, C.A., Lee, V.M., and Klein, P.S. (2003). GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423, 435-439. doi: 10.1038/nature01640.
88. Piatti, P.M., Monti, L.D., Conti, M., Baruffaldi, L., Galli, L., Phan, C.V., Guazzini, B., Pontiroli, A.E., and Pozza, G. (1996). Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 45, 316-321.
89. Potenza, M.A., Marasciulo, F.L., Chieppa, D.M., Brigiani, G.S., Formoso, G., Quon, M.J., and Montagnani, M. (2005). Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 289, H813-822. doi: 10.1152/ajpheart.00092.2005.
90. Potenza, M.A., Marasciulo, F.L., Tarquinio, M., Quon, M.J., and Montagnani, M. (2006). Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance. Diabetes 55, 3594-3603. doi: 10.2337/db06-0667.
91. Qiu, W.Q., Walsh, D.M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M.B., Rosner, M.R., Safavi, A., Hersh, L.B., and Selkoe, D.J. (1998). Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273, 32730-32738.
92. Querfurth, H.W., and Laferla, F.M. (2010). Alzheimer's disease. N Engl J Med 362, 329-344. doi: 10.1056/NEJMra0909142.
93. Rajasekar, N., Dwivedi, S., Nath, C., Hanif, K., and Shukla, R. (2014). Protection of streptozotocin induced insulin receptor dysfunction, neuroinflammation and amyloidogenesis in astrocytes by insulin. Neuropharmacology 86, 337-352. doi: 10.1016/j.neuropharm.2014.08.013.
94. Reger, M.A., Watson, G.S., Frey, W.H., 2nd, Baker, L.D., Cholerton, B., Keeling, M.L., Belongia, D.A., Fishel, M.A., Plymate, S.R., Schellenberg, G.D., Cherrier, M.M., and Craft, S. (2006). Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27, 451-458. doi: 10.1016/j.neurobiolaging.2005.03.016.
95. Reger, M.A., Watson, G.S., Green, P.S., Baker, L.D., Cholerton, B., Fishel, M.A., Plymate, S.R., Cherrier, M.M., Schellenberg, G.D., Frey, W.H., 2nd, and Craft, S. (2008a). Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 13, 323-331.
96. Reger, M.A., Watson, G.S., Green, P.S., Wilkinson, C.W., Baker, L.D., Cholerton, B., Fishel, M.A., Plymate, S.R., Breitner, J.C., Degroodt, W., Mehta, P., and Craft, S. (2008b). Intranasal insulin improves cognition and modulates beta amyloid in early AD. Neurology 70, 440-448. doi: 10.1212/01.wnl.0000265401.62434.36.
97. Rivera, E.J., Goldin, A., Fulmer, N., Tavares, R., Wands, J.R., and De La Monte, S.M. (2005). Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8, 247-268.
98. Rodgers, E.E., and Theibert, A.B. (2002). Functions of PI 3-kinase in development of the nervous system. Int J Dev Neurosci 20, 187-197.
99. Rohn, T.T. (2010). The role of caspases in Alzheimer's disease; potential novel therapeutic opportunities. Apoptosis 15, 1403-1409. doi: 10.1007/s10495-010-0463-2.
100. Rosenbloom, M.H., Barclay, T.R., Pyle, M., Owens, B.L., Cagan, A.B., Anderson, C.P., Frey, W.H., 2nd, and Hanson, L.R. (2014). A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein e4 carriers with mild moderate Alzheimer's disease. CNS Drugs 28, 1185-1189. doi: 10.1007/s40263-014-0214-y.
101. Salehi, Z., Mashayekhi, F., and Naji, M. (2008). Insulin like growth factor-1 and insulin like growth factor binding proteins in the cerebrospinal fluid and serum from patients with Alzheimer's disease. Biofactors 33, 99-106.
102. Saltiel, A.R. (2001). New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104, 517-529.
103. Sarkar, R., Meinberg, E.G., Stanley, J.C., Gordon, D., and Webb, R.C. (1996). Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 78, 225-230.
104. Schlessinger, J. (2000). Cell signaling by receptor tyrosine kinases. Cell 103, 211-225.
105. Schubert, M., Brazil, D.P., Burks, D.J., Kushner, J.A., Ye, J., Flint, C.L., Farhang-Fallah, J., Dikkes, P., Warot, X.M., Rio, C., Corfas, G., and White, M.F. (2003). Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 23, 7084-7092.
106. Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., Kondo, T., Alber, J., Galldiks, N., Kustermann, E., Arndt, S., Jacobs, A.H., Krone, W., Kahn, C.R., and Bruning, J.C. (2004). Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 101, 3100-3105. doi: 10.1073/pnas.0308724101.
107. Schulingkamp, R.J., P agano, T.C., Hung, D., and Raffa, R.B. (2000). Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev 24, 855-872.
108. Selkoe, D.J. (1989). Amyloid beta protein precursor and the pathogenesis of Alzheimer's disease. Cell 58, 611-612.
109. Sesti, G., Federici, M., Hribal, M.L., Lauro, D., Sbraccia, P., and Lauro, R. (2001). Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J 15, 2099-2111. doi: 10.1096/fj.01-0009rev.
110. Sims-Robinson, C., Kim, B., Rosko, A., and Feldman, E.L. (2010). How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6, 551-559. doi: 10.1038/nrneurol.2010.130.
111. Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., and Greengard, P. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci. 8, 1051-8105. doi: 10.1038/nn1503
112. Solano, D.C., Sironi, M., Bonfini, C., Solerte, S.B., Govoni, S., and Racchi, M. (2000). Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J 14, 1015-1022.
113. Son, S.M., Song, H., Byun, J., Park, K.S., Jang, H.C., Park, Y.J., and Mook-Jung, I. (2012). Altered APP processing in insulin-resistant conditions is mediated by autophagosome accumulation via the inhibition of mammalian target of rapamycin pathway. Diabetes 61, 3126-3138. doi: 10.2337/db11-1735.
114. Steen, E., Terry, B.M., Rivera, E.J., Cannon, J.L., Neely, T.R., Tavares, R., Xu, X.J., Wands, J.R., and De La Monte, S.M. (2005). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis 7, 63-80.
115. Stockhorst, U., De Fries, D., Steingrueber, H.J., and Scherbaum, W.A. (2004). Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol Behav 83, 47-54. doi: 10.1016/j.physbeh.2004.07.022.
116. Subramanian, S., and John, M. (2012). Intranasal administration of insulin lowers amyloid-beta levels in rat model of diabetes. Indian J Exp Biol 50, 41-44.
117. Sudoh, S., Frosch, M.P., and Wolf, B.A. (2002). Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry 41, 1091-1099.
118. Talbot, K., Wang, H.Y., Kazi, H., Han, L.Y., Bakshi, K.P., Stucky, A., Fuino, R.L., Kawaguchi, K.R., Samoyedny, A.J., Wilson, R.S., Arvanitakis, Z., Schneider, J.A., Wolf, B.A., Bennett, D.A., Trojanowski, J.Q., and Arnold, S.E. (2012). Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122, 1316-1338. doi: 10.1172/jci59903.
119. Tham, A., Nordberg, A., Grissom, F.E., Carlsson-Skwirut, C., Viitanen, M., and Sara, V.R. (1993). Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm Park Dis Dement Sect 5, 165-176.
120. Thorne, R.G., and Frey, W.H., 2nd (2001). Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 40, 907-946. doi: 10.2165/00003088-200140120-00003.
121. Van Dam, P.S., and Aleman, A. (2004). Insulin- like growth factor-I, cognition and brain aging. Eur J Pharmacol 490, 87-95. doi: 10.1016/j.ejphar.2004.02.047.
122. Van Der Heide, L.P., Ramakers, G.M., and Smidt, M.P. (2006). Insulin signaling in the central nervous system: learning to survive. Prog Neurobiol 79, 205-221. doi: 10.1016/j.pneurobio.2006.06.003.
123. Vardy, E.R., Rice, P.J., Bowie, P.C., Holmes, J.D., Grant, P.J., and Hooper, N.M. (2007). Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. J Alzheimers Dis 12, 285-290.
124. Vekrellis, K., Ye, Z., Qiu, W.Q., Walsh, D., Hartley, D., Chesneau, V., Rosner, M.R., and Selkoe, D.J. (2000). Neurons regulate extracellular levels of amyloid beta protein via proteolysis by insulin-degrading enzyme. J Neurosci 20, 1657-1665.
125. Wada, A., Yokoo, H., Yanagita, T., and Kobayashi, H. (2005). New twist on neuronal insulin receptor signaling in health, disease, and therapeutics. J Pharmacol Sci 99, 128-143.
126. Wadman, M. (2012). US government sets out Alzheimer's plan. Nature 485, 426-427. doi: 10.1038/485426a.
127. Wang, X., Zheng, W., Xie, J.W., Wang, T., Wang, S.L., Teng, W.P., and Wang, Z.Y. (2010). Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener 5, 46. doi: 10.1186/1750-1326-5-46.
128. Wang, Y.L.; Frauwirth, K.A.; Rangwala, S.M.; Lazar, M.A.; Thompson, C.B. Thiazolidinedione Activation of Peroxisome Proliferator-activated Receptor γ Can Enhance Mitochondrial Potential and Promote Cell Survival. (2002) J. Biol.Chem. 277, 31781-31788. doi: 10.1074/jbc.M204279200
129. Watson, G.S., and Craft, S. (2006). Insulin resistance, inflammation, and cognition in Alzheimer's Disease: lessons for multiple sclerosis. J Neurol Sci 245, 21-33. doi: 10.1016/j.jns.2005.08.017.
130. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs. 2003;17(1):27-45.
131. Watson, G.S., Peskind, E.R., Asthana, S., Purganan, K., Wait, C., Chapman, D., Schwartz, M.W., Plymate, S., and Craft, S. (2003). Insulin increases CSF Abeta42 levels in normal older adults. Neurology 60, 1899-1903.
132. Wortmann, M. (2012). Dementia: a global health priority - highlights from an ADI and World Health Organization report. Alzheimers Res Ther 4, 40. doi: 10.1186/alzrt143.
133. Yamamoto, N., Matsubara, T., Sobue, K., Tanida, M., Kasahara, R., Naruse, K., Taniura, H., Sato, T., and Suzuki, K. (2012). Brain insulin resistance accelerates Abeta fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic membranes. J Neurochem 121, 619-628. doi: 10.1111/j.1471-4159.2012.07668.x.
134. Yang, Y., Ma, D., Wang, Y., Jiang, T., Hu, S., Zhang, M., Yu, X., and Gong, C.X. (2013). Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. J Alzheimers Dis 33, 329-338. doi: 10.3233/jad-2012-121294.
135. Yarchoan, M., Toledo, J.B., Lee, E.B., Arvanitakis, Z., Kazi, H., Han, L.Y., Louneva, N., Lee, V.M., Kim, S.F., Trojanowski, J.Q., and Arnold, S.E. (2014). Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. Acta Neuropathol 128, 679-689. doi: 10.1007/s00401-014-1328-5.
136. Zeiher, A.M., Fisslthaler, B., S chray-Utz, B., and Busse, R. (1995). Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 76, 980-986.
137. Zhao, L., Teter, B., Morihara, T., Lim, G.P., Ambegaokar, S.S., Ubeda, O.J., Frautschy, S.A., and Cole, G.M. (2004a). Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 24, 11120-11126. doi: 10.1523/jneurosci.2860-04.2004.
138. Zhao, W.Q., Chen, H., Quon, M.J., and Alkon, D.L. (2004b). Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 490, 71-81. doi: 10.1016/j.ejphar.2004.02.045.
139. Zhao, W.Q., De Felice, F.G., Fernandez, S., Chen, H., Lambert, M.P., Quon, M.J., Krafft, G.A., and Klein, W.L. (2008). Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22, 246-260. doi: 10.1096/fj.06-7703com.
140. Zhao, W.Q., Lacor, P.N., Chen, H., Lambert, M.P., Quon, M.J., Krafft, G.A., and Klein, W.L. (2009). Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J Biol Chem 284, 18742-18753. doi: 10.1074/jbc.M109.011015.
141. Zlokovic, B.V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12, 723-738. doi: 10.1038/nrn3114.